You have read all your free articles, to continue reading subscribe to read the rest of this content.
Ultimovacs has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application on the use of vaccine-checkpoint inhibitor combinations to treat cancer. Subject to grant formalities, it is expected that a patent will issue with a pateAlready a subscriber Login You…
AdjuTec Pharma has announced the approval of ZinChel II in Europe (EPO). This is the most important patent family covering its lead product APC148, it states in a press release. The company has earlier received patent approval in the US and is working with the patent in other major markets…
Nordic Nanovector has announced the grant of a US patent covering the use of Betalutin (177Lu-satetraxetan-lilotomab) for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy (such as rituximab/RTX). The patent strengthens Nordic Nanovector’s overall patent estAlready a subscriber Login You have read all your free articles, to continue…
The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the company’s oral formulation of the GABA-based study drug Remygen. Remygen is currently in Phase 2 development through the ReGenerate-1 trial in individuaAlready a subscriber Login You…
